GPX4 and neoplasm: RSL3 acts by inhibiting the enzymatic activity of GPX4 and irreversibly inactivates GPX4, in which Altretamine and Withaferin A as anti-tumor drugs can directly inhibit GPX4-mediated ferroptosis in tumor cells and provide new strategies for anti-tumor therapy (68, 69).